Despite Side Effects, People Continue Taking Ozempic for Weight Loss

People who lose weight with GLP-1 drugs are likely to continue using the medication despite the side effects. Image Credit: geckophotos/Getty Images

A recent study found that many people using GLP-1 drugs for weight loss choose to continue the medication despite unpleasant side effects. 

Why Some GLP-1 Users Say They’re Developing Scurvy

Reports of people developing scurvy while taking GLP-1 medications are on the rise. Milles Team/Shutterstock

Reports of GLP-1 users developing scurvy have increased in recent months.

GLP-1 drugs can lead to malnutrition since they reduce appetite and food consumption.

GLP-1s Combined With Healthy Habits May Improve Heart Health in Diabetes

Combining GLP-1 drugs with a healthy lifestyle may reduce cardiovascular risks in people with diabetes. Image Credit: Witthaya Prasongsin/Getty Images

A recent study found that people with type 2 diabetes who used GLP-1 receptor agonists (GLP-1 RAs) in combination with healthy lifestyle habits had a reduced risk of major adverse cardiovascular events.

GLP-1 Drugs Like Ozempic May Help Reduce Migraine Symptom Severity

Recent research has found that GLP-1s may reduce the need for emergency care in those with chronic migraine. Image Credit: Maskot/Getty Images

A recent study suggests that GLP-1 drugs, like Ozempic, may make people with chronic migraine less likely to require emergency care. 

People using GLP-1s may be less likely to need new preventive migraine medications. 

Wegovy May Have Higher Risk of ‘Eye Stroke,’ Vision Loss Than Ozempic

Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images

A new study has found that the GLP-1 drug Wegovy is linked with a higher risk of “eye stroke,” especially in men.

Ischemic optic neuropathy (ION) is a rare but serious condition that can cause vision loss or even blindness.

GLP-1 drugs and pregnancy: Who may face higher preterm birth risk

Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes. However, a large study of over 750,000 pregnancies found that there was no link to preterm births or other obstetric complications if the medication was being used to lose weight. The authors of the study, published in Human Reproduction Open, say their findings suggest that it is diabetes rather than the drugs that may be contributing to the increased risk of preterm births.

Structure’s oral GLP-1 data mark bullish year for obesity pills

The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.